LIC IPO, LIC, IPO analysis
Stocks
Aarati Krishnan

IPO Review: LIC IPO – 3 factors to consider before subscribing

The Indian government, deciding to take its chances with market moods, has launched the long-awaited IPO of Life Insurance Corporation of India (LIC). This is entirely an offer for sale by the government to offload 3.5% of its holdings (2.21 crore shares) to the public, at an offer price band of Rs 902-949.  LIC will not receive any proceeds from the sale. Retail bidders will get a Rs 45 discount while LIC’s policyholders will get a Rs 60 discount. 

Premium article available only to subscribers.

Read More
Star Health, Star Health IPO, Star Health and Allied Insurance Co Ltd
Categories
N V Chandrachoodamani

IPO Review: Star Health and Allied Insurance Co Ltd

Star Health and Allied Insurance Co Ltd (Star Health), India’s leading standalone health insurer, is making an IPO worth Rs. 7,249 crore comprising a fresh issue of shares valued at Rs.2,000 crore and an offer for sale of Rs.5,249 crore. The issue will open on November 30 and close on December 2 at a price band of Rs. 870-900 per share.  At the upper end of the price band, Star Health will be valued at Rs. 51,800 crore (~$7 billion).

Premium article available only to subscribers.

Read More
One 97 Communications (Paytm)
Categories
Bhavana Acharya

IPO Review : One 97 Communications (Paytm)

Rs 18,300 crore. This monumental sum is what One 97 Communications Limited, which owns the Paytm platform, aims to mop up in the largest-ever IPO in our markets. To put it in perspective, it is almost twice the size of the largest IPO this year (Zomato at Rs 9375 cr), and as much as the 3 IPOs that we covered recently (Nykaa, FinoBank and PolicyBazaar) combined.

Premium article available only to subscribers.

Read More
PB Fintech, Policybazaar, paisabazaar
Categories
Vidya Bala

IPO review: PB Fintech (Policybazaar) – Should you invest?

At a time when the revenue models for many fintech startups are ambiguous, PB Fintech –  the company that houses Policybazaar and Paisabazaar – stands out. It has a clear revenue model driven by scalability that will likely pave the path to profits!

Premium article available only to subscribers.

Read More
fino payments bank
Categories
N V Chandrachoodamani

IPO Review: Fino Payments Bank Ltd

Fino Payments Bank arrives in the market today with an IPO – a public issue of Rs.1,200 crore comprising fresh issue of shares worth Rs.300 crore and offer for sale of shares worth Rs.900 crore by promoter, Fino Paytech, at a price band of Rs. 560-577 per share.  The issue opens on October 29 and closes on November 2. The proceeds from the fresh issue will go towards augmenting the capital base of the bank. 

Premium article available only to subscribers.

Read More
FSN E-Commerce Ventures
Categories
Aarati Krishnan

IPO Review: FSN E-Commerce Ventures (Nykaa)

FSN E-commerce Ventures, which operates e-commerce platforms in the beauty and fashion spaces under the brand name Nykaa, is launching a Rs 5,350 crore IPO that comprises a fresh issue of shares of Rs 630 crore and an offer for sale of Rs 4,720 crore.

Premium article available only to subscribers.

Read More
Devyani International IPO, Devyani IPO, IPO, Devyani
Categories
Bhavana Acharya

IPO Review: Devyani International – Invest or Avoid?

On the heels of Zomato, Burger King, and Mrs Bectors comes the Devyani International IPO. This company runs the KFC and Pizza Hut chains across the country. It has other restaurant chains too, but the bulk of its revenues come from these two. Devyani International is aiming to raise approximately Rs 1,838 crore through its IPO.

Premium article available only to subscribers.

Read More
glenmark life sciences, glenmark life sciences ipo, IPO review
Categories
N V Chandrachoodamani

IPO Review: Glenmark Life Sciences – Should you invest?

Glenmark Life Sciences (GLS) is a generic API (Active Pharmaceutical Ingredients) manufacturer and a subsidiary of Glenmark Pharmaceuticals. The Glenmark Life Sciences IPO is worth Rs. 1,514 crore, comprising fresh issue of Rs.1,060 crore and an offer for sale worth Rs.454 crore by Glenmark Pharmaceuticals. Should you invest in the IPO of this high-value, non-commoditized API player?

Premium article available only to subscribers.

Read More
zomato ipo, ipo review, zomato
Categories
Bhavana Acharya

IPO Review : Zomato IPO – Invest or avoid?

If there’s talk in the stock markets today, it’s devoted to the upcoming Zomato IPO, which aims to mop up Rs 9,375 crore. Unlike the crop of recent private equity investor backed companies doing IPOs, this isn’t primarily an offer for sale. Zomato gets a whopping Rs 9,000 crore to deploy into its business mainly through a fresh issue of shares. Only one investor, Info Edge, will offload a Rs 375 crore stake. At the upper end of the price band of Rs 72-76, the post-offer market cap of listed Zomato will be around Rs 60,000 crore.

Premium article available only to subscribers.

Read More
GR Infraprojects, IPO Review, GR Infra IPO
Categories
Vidya Bala

IPO Review: GR Infraprojects

In a bull market, when fancied sectors command premium valuations, IPOs in that space also come with a stiff asking price. We have seen this in the chemicals space. However, when a sector has been languishing for long and sees pick up only in pockets, will an IPO from such a sector leave money on the table? More specifically, will GR Infraprojects be one such offer? Read our take.

Premium article available only to subscribers.

Read More
India Pesticides Limited, IPO Review
Categories
N V Chandrachoodamani

IPO Review: India Pesticides Limited

India Pesticides is launching an IPO totalling to Rs 800 crore – with fresh issue of shares worth Rs 100 crore and an offer for sale worth Rs 700 crore by the promoter group. At the upper end of the price band of Rs 290-296 the post-issue market cap of the stock on listing would be Rs3,400 crore and the post-issue price earnings ratio would be 25 times. The offer closes on June 25. The proceeds from fresh issues are planned to be utilised towards working capital requirement and other corporate purposes.

Premium article available only to subscribers.

Read More
Login to your account
OR